Is REMICADE Right for You?
Crohn's disease is an autoimmune condition that affects the digestive tract. Research has shown 
that in Crohn's disease, the body is overproducing a substance known as tumor necrosis factor 
alpha (TNF-alpha). REMICADE® (infliximab) works by neutralizing the biologic activity of this 
substance, which is an important cause of the inflammation processes of Crohn's disease. 
Because REMICADE neutralizes the TNF-alpha, patients may experience a reduction in their 
signs and symptoms of Crohn's disease.

Your doctor may decide that REMICADE is an appropriate treatment option for you.
Although results may vary, a single REMICADE infusion has been shown to reduce the signs 
and symptoms of Crohn's disease in patients with moderately to severely active Crohn's disease 
who have not responded well to conventional therapy. When given as a three-infusion course of 
therapy, REMICADE is also indicated for treatment of patients with fistulizing Crohn's disease 
for the reduction in the number of draining fistula(s).

The efficacy and safety for the use of REMICADE beyond the recommended duration has not 
been established. 

REMICADE is NOT a cure for Crohn's disease. But for many patients, it can lessen the impact 
of Crohn's disease and help them return to a more normal, active life. 

There are reports of serious infections, including sepsis and tuberculosis, that may be life-
threatening. So, if you are prone to or have a history of infections, currently have one, or 
develop one while taking REMICADE, tell your doctor right away. Also tell your doctor before 
beginning treatment if you have had recent close contact with, or if you have had past exposure 
to people with tuberculosis, or if you have any other reason to believe you may be at risk. There 
are also reports of serious infusion reactions with hives, difficulty breathing, and low blood 
pressure. If you have a de-myelinating disease such as multiple sclerosis, tell your doctor before 
you are treated. In rare cases, people with de-myelinating disease who were treated with 
REMICADE have seen their symptoms intensify. Up to one in four people experienced the 
following side effects in clinical studies: upper respiratory infections, headache, cough, sinusitis, 
nausea or mild reactions to the infusion such as rash or itchy skin.